LENZ Therapeutics Inc
LENZ
Company Profile
Business description
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
Contact
201 Lomas Santa Fe Drive
Suite 300
Solana BeachCA92075
USAT: +1 858 925-7000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
42
Stocks News & Analysis
stocks
The best way to get rich and retire early
This goes through the different options including shares, property and business ownership and declares a winner, as well as outlining the mindset needed to earn enough to never have to work again.
stocks
Investors overly negative on cheap ASX share
We cut our fair value by 26% but the market has overreacted.
stocks
Overvalued US AI play reports earnings
Strong earnings with high projected growth but price is too rich.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,000.70 | 41.30 | 0.46% |
| CAC 40 | 8,103.62 | 47.76 | -0.59% |
| DAX 40 | 24,209.94 | 78.46 | -0.32% |
| Dow JONES (US) | 48,257.63 | 122.74 | 0.25% |
| FTSE 100 | 9,841.49 | 55.93 | -0.57% |
| HKSE | 25,801.77 | 111.24 | 0.43% |
| NASDAQ | 23,450.66 | 143.04 | 0.61% |
| Nikkei 225 | 50,402.39 | 895.18 | 1.81% |
| NZX 50 Index | 13,508.30 | 174.90 | 1.31% |
| S&P 500 | 6,868.03 | 33.53 | 0.49% |
| S&P/ASX 200 | 8,699.90 | 39.70 | 0.46% |
| SSE Composite Index | 3,917.36 | 26.92 | 0.69% |